TABLE 1

Overview of Results in Control, PRRT, and PRRT + Lysine Rats

Parameter	Days after therapy	Control (P control vs. PRRT)	PRRT (P PRRT vs. PRRT + lysine)	PRRT + lysine (P control vs. PRRT + lysine)
¹⁷⁷Lu uptake (MBq/kidney)	4	—	3.8 ± 0.3^*	2.0 ± 0.1
BW, % vs. day 0	90	134 ± 3^*	111 ± 6^†	127 ± 5^‡
	140	143 ± 4^*	113 ± 11^†	138 ± 6, NS
Protein in urine (mg/24 h)	100	11 ± 2^*	62 ± 9^*	22 ± 8^*
Urea in serum (mmol/L)	90	5.8 ± 0.2^*	10.5 ± 2.2^‡	7.2 ± 1.0^†
	140	5.3 ± 0.5^*	32.6 ± 9.4^*	7.3 ± 0.6^*
Creatinine in serum (μmol/L)	90	21 ± 2^*	60 ± 5^*	37 ± 3^*
	140	24 ± 1^*	108 ± 20^*	35 ± 4^*
Grading histologic renal damage	140	0.4 ± 0.6^*	4 ± 0^*	1.3 ± 0.5^‡
^99mTc-DMSA (%IA/kidney)	90	13.7 ± 1.4^*	6.4 ± 2.4^*	12.5 ± 1.2, NS
	140	18.1 ± 1.9^*	5.6 ± 3.2^*	14.3 ± 1.1^†
^99mTc-MAG3 (%IA/kidney, 2–6 min)	100–120	13.1 ± 2.6^*	4.3 ± 1.5^*	8.5 ± 1.6^*
^99mTc-MAG3 (%IA/cm³ cortex, 2–6 min)	100–120	6.9 ± 1.9^*	2.6 ± 1.3^‡	3.8 ± 1.0^*
¹¹¹In-DTPA (%IA/kidney, 2–4 min)	100–120	4.7 ± 1.0^†	2.1 ± 1.4, NS	4.4 ± 0.6, NS

↵* P < 0.0001.
↵† P < 0.001.
↵‡ P < 0.05.
NS = not significant.
Quantification of retained renal radioactivity was expressed as total MBq/kidney for ¹⁷⁷Lu and %IA/kidney for ^99mTc-DMSA. Peak activity was expressed as %IA/kidney for ¹¹¹In-DTPA and ^99mTc-MAG3 or as %IA/cm³ cortex for ^99mTc-MAG3. BW of rats was expressed as percentage of BW at day 0. Protein loss in urine was expressed in mg/24-h urine. Serum urea and creatinine content was expressed in mmol/L or μmol/L. Histologic grading of renal damage was expressed on a scale of 0–4.